medigraphic.com
ISSN 2992-779X (Electronic)
ISSN 2007-6452 (Print)

2024, Number 2

<< Back Next >>

Investigación en Discapacidad 2024; 10 (2)

Achondroplasia: 10 years of experience in the clinical approach, management and multidisciplinary care at the National Institute of Rehabilitation ''Luis Guillermo Ibarra Ibarra''

Castañeda-de FA, Mendoza-Hernández IA, Grimaldo-Galiana S, Hidalgo-Bravo A

Language: Spanish
References: 32
Page: 105-111
PDF size: 237.64 Kb.


ABSTRACT

Introduction: achondroplasia is the most common skeletal dysplasia with an incidence of 1 in 20,000-30,000 with 80% of cases being sporadic. It is an autosomal dominant disease, with mutations in the fibroblast growth factor receptor 3 (FGFR3). There are multiple clinical features, the common clinical manifestations include disproportionate short stature with rizhomelic shortening. Material and methods: an observational, retrospective, cross-sectional study was carried out on 42 patients with diagnosis of achondroplasia at the INRLGII between the years 2013 and 2023. We analyzed sex, current age, age at diagnosis, years of follow-up. Results: clinical files of 42 patients were retrieved, 52.4% were men and 47.6% were women. Of all patients, only 9.5% had a prenatal diagnosis. Conclusions: it is essential to carry out a multidisciplinary and proactive approach for the clinical and psychosocial care of people with achondroplasia. And all adults and patients should have access to a clinical geneticist to discuss inheritance patterns.


REFERENCES

  1. Foreman PK, van Kessel F, van Hoorn R, van den Bosch J, Shediac R, Landis S. Birth prevalence of achondroplasia: a systematic literature review and meta-analysis. Am J Med Genet A. 2020; 182: 2297-2316.

  2. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005; 16: 139-149.

  3. Thomson RE, Kind PC, Graham NA, Etherson ML, Kennedy J, Fernandes AC et al. FGF receptor 3 activation promotes selective growth and expansion of occipitotemporal cortex. Neural Dev. 2009; 4: 4.

  4. Daugherty A. Achondroplasia: etiology, clinical presentation, and management. Neonatal Netw. 2017; 36 (6): 337-342. doi: 10.1891/0730-0832.36.6.337.

  5. Horton WA, Hall JG, Hecht JT. Achondroplasia. Lancet. 2007; 370 (9582): 162-172.

  6. Savarirayan R, Ireland P, Irving M, Thompson D, Alves I, Baratela WAR et al. International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia. Nat Rev Endocrinol. 2022; 18 (3): 173-189. doi: 10.1038/s41574-021-00595-x.

  7. Ornitz DM, Legeai-Mallet L. Achondroplasia: development, pathogenesis, and therapy. Dev Dyn. 2017; 246 (4): 291-309. doi: 10.1002/dvdy.24479.

  8. Ireland PJ, Donaghey S, McGill J, Zankl A, Ware RS, Pacey V et al. Development in children with achondroplasia: a prospective clinical cohort study. Dev Med Child Neurol. 2012; 54: 532-537.

  9. White KK, Bompadre V, Goldberg MJ, Bober MB, Campbell JW, Cho TJ et al. Best practices in the evaluation and treatment of foramen magnum stenosis in achondroplasia during infancy. Am J Med Genet A. 2016; 170A (1): 42-51. doi: 10.1002/ajmg.a.37394.

  10. Leiva-Gea A, Martos Lirio MF, Barreda Bonis AC, Marín Del Barrio S, Heath KE, Marín Reina P et al. Achondroplasia: update on diagnosis, follow-up and treatment. An Pediatr (Engl Ed). 2022; 97 (6): 423.e1-423.e11. doi: 10.1016/j.anpede.2022.10.004.

  11. Collins WO, Choi SS. Otolaryngologic manifestations of achondroplasia. Arch Otolaryngol Head Neck Surg. 2007; 133: 237-244.

  12. Berkowitz RG, Grundfast KM, Scott C, Saal H, Stern H, Rosenbaum K. Middle ear disease in childhood achondroplasia. Ear Nose Throat J. 1991; 70: 305-308.

  13. Ireland PJ, Pacey V, Zankl A, Edwards P, Johnston LM, Savarirayan R. Optimal management of complications associated with achondroplasia. Appl Clin Genet. 2014; 7: 117-125.

  14. Wrobel W, Pach E, Ben-Skowronek I. Advantages and disadvantages of different treatment methods in achondroplasia: a review. Int J Mol Sci. 2021; 22 (11): 5573.

  15. "Voxzogo APMDS". Therapeutic goods administration (TGA). 4 August 2022. Archived from the original on 6 August 2022. Retrieved 6 August 2022.

  16. Clinical trial number NCT02055157 for "A phase 2 study of BMN 111 to evaluate safety, tolerability, and efficacy in children with achondroplasia (ACH)" at ClinicalTrials.gov

  17. Duggan S. Vosoritide: first approval. Drugs. 2021; 81 (17): 2057-2062. doi: 10.1007/s40265-021-01623-w.

  18. Komla-Ebri D, Dambroise E, Kramer I, Benoist-Lasselin C, Kaci N, Le Gall C et al. Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model. J Clin Invest. 2016; 126 (5): 1871-1884.

  19. Lacouture ME, Sibaud V, Anadkat MJ, Kaffenberger B, Leventhal J, Guindon K et al. Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines. Oncologist. 2021; 26 (2): e316-e326.

  20. Godoy Escobar I. Acondroplasia: revisión de 30 años en el Instituto Nacional de Pediatría [Tesis]. México: Instituto Nacional de Rehabilitación; 2004. http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/633

  21. Guzmán-Huerta ME, Morales AS, Benavides-Serralde A, Camargo-Marín L, Velázquez-Torres B, Gallardo-Gaona JM et al. Prenatal prevalence of skeletal dysplasias and a proposal ultrasonographic diagnosis approach. Rev Invest Clin. 2012; 64 (5): 429-436.

  22. Kallén B, Knudsen LB, Mutchinick O, Mastroiacovo P, Lancaster P, Castilla E et al. Monitoring dominant germ cell mutations using skeletal dysplasias registered in malformation registries: an international feasibility study. Int J Epidemiol. 1993; 22 (1): 107-115.

  23. Pauli RM. Achondroplasia: a comprehensive clinical review. Orphanet J Rare Dis. 2019; 14 (1): 1. doi: 10.1186/s13023-018-0972-6.

  24. Hoover-Fong JE, Alade AY, Hashmi SS, Hecht JT, Legare JM, Little ME et al. Achondroplasia Natural History Study (CLARITY): a multicenter retrospective cohort study of achondroplasia in the United States. Genet Med. 2021; 23 (8): 1498-1505. doi: 10.1038/s41436-021-01165-2.

  25. Savarirayan R, Irving M, Harmatz P, Delgado B, Wilcox WR, Philips J et al. Growth parameters in children with achondroplasia: A 7-year, prospective, multinational, observational study. Genet Med. 2022; 24 (12): 2444-2452. doi: 10.1016/j.gim.2022.08.015.

  26. Cormier-Daire V, AlSayed M, Ben-Omran T, de Sousa SB, Boero S, Fredwall SO et al. The first European Consensus on principles of management for achondroplasia. Orphanet J Rare Dis. 2021; 16 (1): 333. doi: 10.1186/s13023-021-01971-6.

  27. Maghnie M, Bruzzi P, Casilli G, Lidonnici D, Scarano G. The management of achondroplasia in Italy: results from a Delphi panel based on real-world experience. Front Pediatr. 2023; 11: 1209994. doi: 10.3389/fped.2023.1209994.

  28. Llerena J Jr, Kim CA, Fano V, Rosselli P, Collett-Solberg PF, de Medeiros PFV et al. Achondroplasia in Latin America: practical recommendations for the multidisciplinary care of pediatric patients. BMC Pediatr. 2022; 22 (1): 492. doi: 10.1186/s12887-022-03505-w.

  29. Pesl M, Verescakova H, Skutkova L, Strenkova J, Krejci P. A registry of achondroplasia: a 6-year experience from the Czechia and Slovak Republic. Orphanet J Rare Dis. 2022; 17 (1): 229. doi: 10.1186/s13023-022-02374-x.

  30. Goyal M, Gupta A, Bhandari A, Faruq M. Achondroplasia: clinical, radiological and molecular profile from rare disease Centre, India. J Pediatr Genet. 2021; 12 (1): 42-47. doi: 10.1055/s-0041-1731684.

  31. Del Pino M, Fano V, Adamo P. Growth in achondroplasia, from birth to adulthood, analysed by the JPA-2 model. J Pediatr Endocrinol Metab. 2020; 33 (12): 1589-1595. doi: 10.1515/jpem-2020-0298.

  32. Yonko EA, Emanuel JS, Carter EM, Raggio CL. Quality of life in adults with achondroplasia in the United States. Am J Med Genet A. 2021; 185 (3): 695-701. doi: 10.1002/ajmg.a.62018.




2020     |     www.medigraphic.com